Brief Report: Blockade of TANK‐Binding Kinase 1/IKKɛ Inhibits Mutant Stimulator of Interferon Genes (STING)–Mediated Inflammatory Responses in Human Peripheral Blood Mononuclear Cells

Gain‐of‐function mutations in TMEM173, encoding the stimulator of interferon (IFN) genes (STING) protein, underlie a novel type I interferonopathy that is minimally responsive to conventional immunosuppressive therapies and associated with high frequency of childhood morbidity and mortality. STING gain‐of‐function causes constitutive oversecretion of IFN. This study was undertaken to determine the effects of a TANK‐binding kinase 1 (TBK‐1)/IKKɛ inhibitor (BX795) on secretion and signaling of IFN in primary peripheral blood mononuclear cells (PBMCs) from patients with mutations in STING.

[1]  F. Rieux-Laucat,et al.  Disease‐associated mutations identify a novel region in human STING necessary for the control of type I interferon signaling , 2017, The Journal of allergy and clinical immunology.

[2]  F. Rieux-Laucat,et al.  Detection of interferon alpha protein reveals differential levels and cellular sources in disease , 2017, The Journal of experimental medicine.

[3]  F. Rieux-Laucat,et al.  Efficacy of the Janus kinase 1/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173-activating mutations in 3 children. , 2016, The Journal of allergy and clinical immunology.

[4]  F. Rieux-Laucat,et al.  Severe Pulmonary Fibrosis as the First Manifestation of Interferonopathy (TMEM173 Mutation). , 2016, Chest.

[5]  Hedi Peterson,et al.  AIRE-Deficient Patients Harbor Unique High-Affinity Disease-Ameliorating Autoantibodies , 2016, Cell.

[6]  K. Elkon,et al.  Neutrophil extracellular traps enriched in oxidized mitochondrial DNA are interferogenic and contribute to lupus-like disease , 2015, Nature Medicine.

[7]  Nan Yan,et al.  Cutting Edge: Inhibiting TBK1 by Compound II Ameliorates Autoimmune Disease in Mice , 2015, The Journal of Immunology.

[8]  G. Cheng,et al.  Positive feedback regulation of type I interferon by the interferon‐stimulated gene STING , 2015, EMBO reports.

[9]  T. Molina,et al.  Inherited STING-activating mutation underlies a familial inflammatory syndrome with lupus-like manifestations. , 2014, The Journal of clinical investigation.

[10]  Ha Won Kim,et al.  Activated STING in a vascular and pulmonary syndrome. , 2014, The New England journal of medicine.

[11]  J. Casanova,et al.  STING-associated vasculopathy with onset in infancy--a new interferonopathy. , 2014, The New England journal of medicine.

[12]  A. Vanderver,et al.  Assessment of interferon-related biomarkers in Aicardi-Goutières syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case-control study , 2013, The Lancet Neurology.

[13]  Steven M Holland,et al.  JAKs and STATs in immunity, immunodeficiency, and cancer. , 2013, The New England journal of medicine.

[14]  Jason Gotlib,et al.  A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. , 2012, The New England journal of medicine.

[15]  P. Cohen,et al.  Use of the pharmacological inhibitor BX795 to study the regulation and physiological roles of TBK1 and IkappaB kinase epsilon: a distinct upstream kinase mediates Ser-172 phosphorylation and activation. , 2009, The Journal of biological chemistry.

[16]  T. Heidmann,et al.  Trex1 Prevents Cell-Intrinsic Initiation of Autoimmunity , 2008, Cell.

[17]  T. Maniatis,et al.  Multiple Functions of the IKK-Related Kinase IKKε in Interferon-Mediated Antiviral Immunity , 2007, Science.

[18]  J. Prieto,et al.  The protein kinase IKKε can inhibit HCV expression independently of IFN and its own expression is downregulated in HCV‐infected livers , 2006, Hepatology.